GlassScriptPhysician profile
Carissa M Spain
NPI 1053656116
$2,499.08
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $907 · 2022: $636 · 2023: $791 · 2024: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $956.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $389.35 | 2021-2024 | |
| Amgen INC. | $278.56 | 2021-2024 | Repatha, Otezla |
| Novo Nordisk INC | $260.95 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $196.78 | 2021-2023 | Breztri, Farxiga |
| Astellas Pharma US INC | $168.70 | 2022-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $167.46 | 2021-2023 | |
| Mylan Specialty L.P. | $112.13 | 2021-2023 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.01 | 2021-2023 | Trijardy Xr, Tradjenta, Glyxambi |
| Novartis Pharmaceuticals Corporation | $98.91 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $97.26 | 2021-2022 | |
| Sanofi Pasteur INC. | $87.53 | 2021-2024 | |
| Lilly USA, LLC | $86.18 | 2021-2024 | Mounjaro, Emgality, Jardiance |
| Kowa Pharmaceuticals America, INC. | $75.52 | 2021-2023 | Seglentis, Livalo |
| Biohaven Pharmaceutical Holding Company LTD. | $58.57 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $48.75 | 2022-2023 | Rexulti |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $47.22 | 2022-2023 | Wakix |
| Takeda Pharmaceuticals U.S.A., INC. | $41.72 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $40.98 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $29.95 | 2021 | |
| Exact Sciences Corporation | $28.57 | 2023 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $25.12 | 2021-2022 | |
| Glaxosmithkline, LLC. | $17.45 | 2023 | Arexvy |
| Nestle Healthcare Nutrition INC. | $15.89 | 2021 | |
| Esperion Therapeutics, INC. | $13.96 | 2021 | |
| Genentech USA, INC. | $9.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carissa Spain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.